Locoregional recurrence in patients with HER2 positive breast cancer

Breast. 2013 Oct;22(5):856-62. doi: 10.1016/j.breast.2013.03.010. Epub 2013 May 1.

Abstract

Literature shows that HER2/neu positive breast cancer cells are more sensitive to radiation-induced apoptosis by targeting the epidermal growth factor receptor family tyrosine kinase. We selected 466 patients with pT1-2 HER2/neu positive tumors who received adjuvant trastuzumab for primary invasive breast cancer. Patients were divided into three groups [Quadrantectomy followed by conventional radiotherapy vs Quadrantectomy followed by Intra-operative radiotherapy with electrons vs Mastectomy without radiotherapy]. After a median follow-up of 52 months, the 5-year cumulative incidence of locoregional recurrence (LRR) was 1.9%, 11.5% and 5.0% respectively (p < 0.01). At the multivariate analysis, extensive perivascular invasion, Luminal B HER2/Progesterone Receptor (PgR) negative status and Quadrantectomy followed by Intra-operative radiotherapy with electrons have significantly increased the risk of LRR. Our results suggest that HER2/neu positive breast cancer might have better outcomes when treated simultaneously with external radiotherapy and trastuzumab. Moreover, we underline the importance of PgR and further new stratification of risk among luminal subtypes.

Keywords: Breast cancer; HER2/neu; Locoregional recurrence; Radiation therapy; Trastuzumab.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / therapy*
  • Carcinoma / chemistry
  • Carcinoma / therapy*
  • Chemotherapy, Adjuvant
  • Female
  • Humans
  • Ki-67 Antigen / analysis
  • Mastectomy, Segmental
  • Middle Aged
  • Neoplasm Recurrence, Local* / chemistry
  • Radiotherapy, Adjuvant / methods
  • Receptor, ErbB-2 / analysis
  • Receptors, Progesterone / analysis
  • Retrospective Studies
  • Trastuzumab
  • Young Adult

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Ki-67 Antigen
  • Receptors, Progesterone
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab